Correction to: S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102) (International Journal of Clinical Oncology, (2016), 21, 4, (705-712), 10.1007/s10147-015-0943-z)

Yuji Miyamoto, Akihito Tsuji, Hiroaki Tanioka, Soichiro Maekawa, Hirofumi Kawanaka, Masaki Kitazono, Eiji Oki, Yasunori Emi, Hidetsugu Murakami, Yutaka Ogata, Hiroshi Saeki, Mototsugu Shimokawa, Shoji Natsugoe, Yoshito Akagi, Hideo Baba, Yoshihiko Maehara

研究成果: ジャーナルへの寄稿コメント/討論

抄録

In the original publication, in Abstract, the sentence that reads as, “Oral S-1 at a dose of 80 mg/m2 was. drug-free interval” should read as, “Oral S-1 at a dose of 40 mg/m2 was administered twice daily for 2 weeks, followed by a 1-week drug-free interval.

元の言語英語
ページ数1
ジャーナルInternational Journal of Clinical Oncology
23
発行部数2
DOI
出版物ステータス出版済み - 4 1 2018

Fingerprint

oxaliplatin
irinotecan
Medical Oncology
Colorectal Neoplasms
Japan
Drug Therapy
Pharmaceutical Preparations
Publications
Bevacizumab

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hematology
  • Oncology

これを引用

Correction to : S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102) (International Journal of Clinical Oncology, (2016), 21, 4, (705-712), 10.1007/s10147-015-0943-z). / Miyamoto, Yuji; Tsuji, Akihito; Tanioka, Hiroaki; Maekawa, Soichiro; Kawanaka, Hirofumi; Kitazono, Masaki; Oki, Eiji; Emi, Yasunori; Murakami, Hidetsugu; Ogata, Yutaka; Saeki, Hiroshi; Shimokawa, Mototsugu; Natsugoe, Shoji; Akagi, Yoshito; Baba, Hideo; Maehara, Yoshihiko.

:: International Journal of Clinical Oncology, 巻 23, 番号 2, 01.04.2018.

研究成果: ジャーナルへの寄稿コメント/討論

Miyamoto, Yuji ; Tsuji, Akihito ; Tanioka, Hiroaki ; Maekawa, Soichiro ; Kawanaka, Hirofumi ; Kitazono, Masaki ; Oki, Eiji ; Emi, Yasunori ; Murakami, Hidetsugu ; Ogata, Yutaka ; Saeki, Hiroshi ; Shimokawa, Mototsugu ; Natsugoe, Shoji ; Akagi, Yoshito ; Baba, Hideo ; Maehara, Yoshihiko. / Correction to : S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102) (International Journal of Clinical Oncology, (2016), 21, 4, (705-712), 10.1007/s10147-015-0943-z). :: International Journal of Clinical Oncology. 2018 ; 巻 23, 番号 2.
@article{7bfea3e9dc21488e9ffcc28e3ecc6723,
title = "Correction to: S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102) (International Journal of Clinical Oncology, (2016), 21, 4, (705-712), 10.1007/s10147-015-0943-z)",
abstract = "In the original publication, in Abstract, the sentence that reads as, “Oral S-1 at a dose of 80 mg/m2 was. drug-free interval” should read as, “Oral S-1 at a dose of 40 mg/m2 was administered twice daily for 2 weeks, followed by a 1-week drug-free interval.",
author = "Yuji Miyamoto and Akihito Tsuji and Hiroaki Tanioka and Soichiro Maekawa and Hirofumi Kawanaka and Masaki Kitazono and Eiji Oki and Yasunori Emi and Hidetsugu Murakami and Yutaka Ogata and Hiroshi Saeki and Mototsugu Shimokawa and Shoji Natsugoe and Yoshito Akagi and Hideo Baba and Yoshihiko Maehara",
year = "2018",
month = "4",
day = "1",
doi = "10.1007/s10147-017-1212-0",
language = "English",
volume = "23",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Correction to

T2 - S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102) (International Journal of Clinical Oncology, (2016), 21, 4, (705-712), 10.1007/s10147-015-0943-z)

AU - Miyamoto, Yuji

AU - Tsuji, Akihito

AU - Tanioka, Hiroaki

AU - Maekawa, Soichiro

AU - Kawanaka, Hirofumi

AU - Kitazono, Masaki

AU - Oki, Eiji

AU - Emi, Yasunori

AU - Murakami, Hidetsugu

AU - Ogata, Yutaka

AU - Saeki, Hiroshi

AU - Shimokawa, Mototsugu

AU - Natsugoe, Shoji

AU - Akagi, Yoshito

AU - Baba, Hideo

AU - Maehara, Yoshihiko

PY - 2018/4/1

Y1 - 2018/4/1

N2 - In the original publication, in Abstract, the sentence that reads as, “Oral S-1 at a dose of 80 mg/m2 was. drug-free interval” should read as, “Oral S-1 at a dose of 40 mg/m2 was administered twice daily for 2 weeks, followed by a 1-week drug-free interval.

AB - In the original publication, in Abstract, the sentence that reads as, “Oral S-1 at a dose of 80 mg/m2 was. drug-free interval” should read as, “Oral S-1 at a dose of 40 mg/m2 was administered twice daily for 2 weeks, followed by a 1-week drug-free interval.

UR - http://www.scopus.com/inward/record.url?scp=85033670000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033670000&partnerID=8YFLogxK

U2 - 10.1007/s10147-017-1212-0

DO - 10.1007/s10147-017-1212-0

M3 - Comment/debate

AN - SCOPUS:85033670000

VL - 23

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 2

ER -